{
    "clinical_study": {
        "@rank": "35324", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects will be maintained on oral placebo."
            }, 
            {
                "arm_group_label": "n-Acetylcysteine", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will be maintained on oral n-acetylcysteine."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will determine the initial efficacy, safety and tolerability of n-acetylcysteine\n      as a pharmacotherapy for cocaine dependence. A rigorous, inpatient human laboratory study\n      will be conducted in which the subjective, physiological and reinforcing effects of cocaine\n      are evaluated during maintenance on placebo and n-acetylcysteine."
        }, 
        "brief_title": "n-Acetylcysteine and Cocaine", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Cocaine Abuse", 
            "Cocaine Dependence"
        ], 
        "condition_browse": {
            "mesh_term": "Cocaine-Related Disorders"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Current cocaine use\n\n          -  Current cigarette smoker\n\n        Exclusion Criteria:\n\n          -  Abnormal screening outcome (e.g., ECG, blood chemistry result) that study physicians\n             deem clinically significant\n\n          -  Current or past histories of substance abuse or dependence that are deemed by the\n             study physicians to interfere with study completion\n\n          -  History of serious physical disease, current physical disease, impaired\n             cardiovascular functioning, chronic obstructive pulmonary disease, history of seizure\n             or current or past histories of serious psychiatric disorder that in the opinion of\n             the study physician would interfere with study participation will be excluded from\n             participation\n\n          -  Females not currently using effective birth control\n\n          -  Contraindications to cocaine or n-acetylcysteine\n\n          -  History of schizophrenia in first degree relative"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "44 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "14", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02141620", 
            "org_study_id": "R21DA035376"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Placebo", 
                    "n-Acetylcysteine"
                ], 
                "description": "The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and n-acetylcysteine.", 
                "intervention_name": "Cocaine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "n-Acetylcysteine", 
                "intervention_name": "n-Acetylcysteine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Acetylcysteine", 
                "N-monoacetylcystine", 
                "Cocaine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 14, 2014", 
        "location": {
            "contact": {
                "email": "william.stoops@uky.edu", 
                "last_name": "William W Stoops, PhD", 
                "phone": "859-257-5388"
            }, 
            "facility": {
                "address": {
                    "city": "Lexington", 
                    "country": "United States", 
                    "state": "Kentucky", 
                    "zip": "40507"
                }, 
                "name": "University of Kentucky Laboratory of Human Behavioral Pharmacology"
            }, 
            "investigator": {
                "last_name": "William W Stoops, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Motivation for Cocaine and Non-Drug Reinforcers: Targeting Glutamate Homeostasis", 
        "overall_contact": {
            "email": "william.stoops@uky.edu", 
            "last_name": "William W Stoops, Ph.D.", 
            "phone": "859-257-5388"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The reinforcing effects of cocaine will be determined using a self-administration procedure in which subjects choose to take previously sampled doses. Reinforcing effects are measured during maintenance on placebo and n-acetylcysteine.", 
            "measure": "Reinforcing Effects", 
            "safety_issue": "No", 
            "time_frame": "After at least seven days of placebo or n-acetylcysteine maintenance"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02141620"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Kentucky", 
            "investigator_full_name": "William Stoops", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Subjects will complete subjective effects measures during six sessions while they are admitted to our inpatient unit. These items will ask about drug effects and general mood.", 
                "measure": "Subjective Effects", 
                "safety_issue": "Yes", 
                "time_frame": "6 sessions over approximately 2 week inpatient admissions"
            }, 
            {
                "description": "Physiological measures will be completed daily while subjects are admitted to our inpatient unit. Physiological measures include heart rate and blood pressure.", 
                "measure": "Physiological Effects", 
                "safety_issue": "Yes", 
                "time_frame": "Daily over approximately 2 week inpatient admissions"
            }, 
            {
                "description": "Subjects will complete a side effects questionnaire daily while they reside on the inpatient unit. Side Effects questions will query subjects about common effects of centrally active medications.", 
                "measure": "Side Effects", 
                "safety_issue": "Yes", 
                "time_frame": "Daily over approximately two weeks of inpatient admission."
            }
        ], 
        "source": "University of Kentucky", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institute on Drug Abuse (NIDA)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of Kentucky", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}